197 related articles for article (PubMed ID: 32847588)
1. Potential prognostic value of delta-like protein 3 in small cell lung cancer: a meta-analysis.
Chen B; Li H; Liu C; Wang S; Zhang F; Zhang L; Li M; Li G
World J Surg Oncol; 2020 Aug; 18(1):226. PubMed ID: 32847588
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of delta-like3 and serum NSE in evaluating chemotherapy response and prognosis in patients with advanced small cell lung carcinoma: An observational study.
Zhu C; Huang J; Jin X; Zhang C; Zhu C; Lv M; Chen S; Du X; Feng G
Medicine (Baltimore); 2024 Jun; 103(23):e38487. PubMed ID: 38847733
[TBL] [Abstract][Full Text] [Related]
3. Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer.
Bylsma LC; Pundole X; Ju CH; Hooda N; Movva N; Elkhouly E; Bebb G; Fryzek J; Martinez P; Balasubramanian A; Dingemans AC
Target Oncol; 2023 Nov; 18(6):821-835. PubMed ID: 37930513
[TBL] [Abstract][Full Text] [Related]
4. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
5. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
[TBL] [Abstract][Full Text] [Related]
6. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
Huang J; Cao D; Sha J; Zhu X; Han S
Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
[TBL] [Abstract][Full Text] [Related]
7. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
[TBL] [Abstract][Full Text] [Related]
8. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
[TBL] [Abstract][Full Text] [Related]
9. International real-world study of DLL3 expression in patients with small cell lung cancer.
Rojo F; Corassa M; Mavroudis D; Öz AB; Biesma B; Brcic L; Pauwels P; Sailer V; Gosney J; Miljkovic D; Hader C; Wu M; Almarez T; Penault-Llorca F
Lung Cancer; 2020 Sep; 147():237-243. PubMed ID: 32745892
[TBL] [Abstract][Full Text] [Related]
10. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
Furuta M; Kikuchi H; Shoji T; Takashima Y; Kikuchi E; Kikuchi J; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J
Cancer Sci; 2019 May; 110(5):1599-1608. PubMed ID: 30874360
[TBL] [Abstract][Full Text] [Related]
11. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
Tanaka K; Isse K; Fujihira T; Takenoyama M; Saunders L; Bheddah S; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Jan; 115():116-120. PubMed ID: 29290251
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC.
Li W; Ye L; Huang Y; Zhou F; Wu C; Wu F; He Y; Li X; Wang H; Xiong A; Gao G; Wang L; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2022 May; 167():25-33. PubMed ID: 35381444
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of delta-like protein 3 combined with thyroid transcription factor-1 in small-cell lung cancer.
Yan LX; Liu YH; Li Z; Luo DL; Li YF; Yan JH; Zhang JT; Liu C; Liu XH; He J
Oncol Lett; 2019 Sep; 18(3):2254-2261. PubMed ID: 31452726
[TBL] [Abstract][Full Text] [Related]
16. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
[TBL] [Abstract][Full Text] [Related]
17. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.
Liu M; Huang W; Guo Y; Zhou Y; Zhi C; Chen J; Li J; He J; Lian H; Zhou J; Ye X; Hu Y; Hu H; Liu Z; Huang J; Lin L; Cai M; Wang X; Huang J; Zhang Z; Zhu K; Zhao Q; Cao B
J Leukoc Biol; 2022 Oct; 112(4):901-911. PubMed ID: 35088475
[TBL] [Abstract][Full Text] [Related]
18. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer.
Regzedmaa O; Li Y; Li Y; Zhang H; Wang J; Gong H; Yuan Y; Li W; Liu H; Chen J
Onco Targets Ther; 2019; 12():10043-10055. PubMed ID: 31819500
[TBL] [Abstract][Full Text] [Related]
20. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
